Fairbanks Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.3M | Sell |
21,986
-1,004
| -4% | -$220K | 3.14% | 14 |
|
|
2026
Q1 | $4.35M | Sell |
22,990
-429
| -2% | -$75K | 2.72% | 15 |
|
|
2025
Q4 | $3.98M | Sell |
23,419
-1,604
| -6% | -$246K | 2.2% | 16 |
|
|
2025
Q3 | $3.3M | Buy |
25,023
+94
| +0.4% | +$11.3K | 1.79% | 19 |
|
|
2025
Q2 | $2.65M | Sell |
24,929
-2
| -0% | -$217 | 1.51% | 23 |
|
|
2025
Q1 | $3.1M | Sell |
24,931
-4,195
| -14% | -$547K | 1.99% | 18 |
|
|
2024
Q4 | $3.59M | Buy |
29,126
+1,592
| +6% | +$188K | 2.23% | 16 |
|
|
2024
Q3 | $3.07M | Buy |
27,534
+422
| +2% | +$46.2K | 1.93% | 18 |
|
|
2024
Q2 | $2.89M | Buy |
27,112
+1,178
| +5% | +$130K | 1.9% | 18 |
|
|
2024
Q1 | $3.12M | Sell |
25,934
-567
| -2% | -$69.5K | 2.15% | 17 |
|
|
2023
Q4 | $3.26M | Buy |
26,501
+2,890
| +12% | +$361K | 2.33% | 17 |
|
|
2023
Q3 | $3.06M | Buy |
23,611
+1,543
| +7% | +$206K | 2.57% | 13 |
|
|
2023
Q2 | $2.74M | Sell |
22,068
-979
| -4% | -$132K | 2.13% | 17 |
|
|
2023
Q1 | $3.37M | Buy |
23,047
+688
| +3% | +$102K | 2.68% | 11 |
|
|
2022
Q4 | $3.56M | Sell |
22,359
-5,516
| -20% | -$808K | 3.17% | 11 |
|
|
2022
Q3 | $3.71M | Sell |
27,875
-325
| -1% | -$49.4K | 3.46% | 8 |
|
|
2022
Q2 | $4.4M | Sell |
28,200
-240
| -0.8% | -$36.9K | 3.83% | 8 |
|
|
2022
Q1 | $4.43M | Buy |
28,440
+1,021
| +4% | +$148K | 3.29% | 9 |
|
|
2021
Q4 | $3.49M | Buy |
27,419
+69
| +0.3% | +$9.07K | 2.54% | 14 |
|
|
2021
Q3 | $3.56M | Sell |
27,350
-113
| -0.4% | -$17.1K | 2.91% | 11 |
|
|
2021
Q2 | $4.88M | Buy |
27,463
+115
| +0.4% | +$19.9K | 3.85% | 7 |
|
|
2021
Q1 | $4.5M | Sell |
27,348
-580
| -2% | -$95.4K | 3.67% | 6 |
|
|
2020
Q4 | $4.61M | Sell |
27,928
-392
| -1% | -$58.4K | 4.13% | 6 |
|
|
2020
Q3 | $4.04M | Sell |
28,320
-995
| -3% | -$123K | 4.04% | 6 |
|
|
2020
Q2 | $3.61M | Buy |
29,315
+660
| +2% | +$73K | 3.53% | 8 |
|
|
2020
Q1 | $2.86M | Sell |
28,655
-5,305
| -16% | -$686K | 3.74% | 6 |
|
|
2019
Q4 | $5.07M | Sell |
33,960
-1,497
| -4% | -$204K | 5.24% | 3 |
|
|
2019
Q3 | $4.54M | Buy |
35,457
+448
| +1% | +$60.1K | 4.68% | 6 |
|
|
2019
Q2 | $4.99M | Buy |
35,009
+140
| +0.4% | +$18.8K | 5.32% | 5 |
|
|
2019
Q1 | $4.99M | Buy |
34,869
+452
| +1% | +$59K | 5.09% | 5 |
|
|
2018
Q4 | $4.27M | Buy |
34,417
+3,814
| +12% | +$566K | 4.72% | 4 |
|
|
2018
Q3 | $5.14M | Sell |
30,603
-19
| -0.1% | -$3.27K | 5.14% | 5 |
|
|
2018
Q2 | $5.28M | Buy |
30,622
+60
| +0.2% | +$9.81K | 6.18% | 4 |
|
|
2018
Q1 | $4.62M | Sell |
30,562
-583
| -2% | -$85.5K | 4.66% | 6 |
|
|
2017
Q4 | $4.19M | Sell |
31,145
-185
| -0.6% | -$25.7K | 3.85% | 6 |
|
|
2017
Q3 | $4.58M | Sell |
31,330
-10
| -0% | -$1.51K | 4.44% | 6 |
|
|
2017
Q2 | $4.87M | Sell |
31,340
-3,190
| -9% | -$488K | 4.57% | 6 |
|
|
2017
Q1 | $5.01M | Buy |
34,530
+1,035
| +3% | +$135K | 4.93% | 6 |
|
|
2016
Q4 | $3.65M | Buy |
33,495
+1,896
| +6% | +$211K | 3.77% | 6 |
|
|
2016
Q3 | $3.84M | Sell |
31,599
-976
| -3% | -$132K | 4.14% | 6 |
|
|
2016
Q2 | $4.6M | Buy |
+32,575
| New | +$4.8M | 5.52% | 6 |
|
Other funds holding JAZZ
Fairbanks Capital Management's JAZZ Position: Q2 2026 in Review
Fairbanks Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 4.4% in Q2 2026, selling an estimated $220K and leaving 21,986 shares worth $5.3M. The position accounts for 3.14% of the portfolio, ranked #14.
Fairbanks Capital Management first reported a position in JAZZ in Q2 2016 and has held it in 41 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Fairbanks Capital Management held 21,986 shares of Jazz Pharmaceuticals worth $5.3M as of Q2 2026.
- Fairbanks Capital Management sold 1,004 Jazz Pharmaceuticals shares in Q2 2026, an estimated $220K.
- Jazz Pharmaceuticals made up 3.14% of Fairbanks Capital Management's portfolio in Q2 2026, its #14 holding.
- Fairbanks Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Fairbanks Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.